Shares of Bellerophon Therapeutics Inc (NASDAQ:BLPH) have earned an average broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the company, Zacks Investment Research reports. One analyst has rated the stock with a strong buy rating.

Brokerages have set a 12-month consensus target price of $5.00 for the company and are expecting that the company will post ($0.24) EPS for the current quarter, according to Zacks. Zacks has also given Bellerophon Therapeutics an industry rank of 154 out of 265 based on the ratings given to its competitors.

Separately, Zacks Investment Research cut Bellerophon Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, September 14th.

Bellerophon Therapeutics (NASDAQ:BLPH) opened at $2.12 on Friday. The stock has a market capitalization of $75.28 and a PE ratio of -1.63. Bellerophon Therapeutics has a 52-week low of $0.57 and a 52-week high of $2.74.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its holdings in shares of Bellerophon Therapeutics by 52.6% in the 2nd quarter. Vanguard Group Inc. now owns 612,641 shares of the biotechnology company’s stock worth $821,000 after acquiring an additional 211,111 shares during the period. Susquehanna International Group LLP acquired a new stake in shares of Bellerophon Therapeutics in the 2nd quarter worth approximately $1,316,000. Finally, VHCP Management II LLC acquired a new stake in shares of Bellerophon Therapeutics in the 3rd quarter worth approximately $4,720,000. Institutional investors and hedge funds own 43.51% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Brokerages Set $5.00 Price Target for Bellerophon Therapeutics Inc (BLPH)” was first posted by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The legal version of this piece of content can be viewed at

Bellerophon Therapeutics Company Profile

Bellerophon Therapeutics, Inc is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension (PH), using its delivery system, INOpulse, with pulmonary arterial hypertension (PAH) as the lead indication.

Get a free copy of the Zacks research report on Bellerophon Therapeutics (BLPH)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with's FREE daily email newsletter.